Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-CD73 monoclonal antibody NZV930

A fully human monoclonal antibody targeting the ectoenzyme 5'-ecto-nucleotidase (cluster of differentiation 73; CD73; 5'-NT; ecto-5'-nucleotidase; NT5E), with potential immunomodulating and antineoplastic activities. Upon intravenous administration, anti-CD73 monoclonal antibody NZV930 targets and binds to CD73 on tumor cells, leading to internalization of CD73. This prevents CD73-mediated conversion of extracellular adenosine monophosphate (AMP) to adenosine, thereby preventing adenosine-mediated suppression of lymphocyte activity and increasing the activity of cytotoxic T lymphocytes (CTLs). This also activates macrophages and reduces the activity of both myeloid-derived suppressor cells (MDSCs) and regulatory T lymphocytes. By abrogating the inhibitory effect on the immune system and enhancing the CTL-mediated immune response against cancer cells, tumor cell growth is decreased. CD73, a plasma membrane protein belonging to the 5'-nucleotidase (NTase) family, is upregulated in many cancer cell types and catalyzes the conversion of extracellular nucleotides, such as AMP, to membrane-permeable nucleosides, such as adenosine; it plays a key role in adenosine-mediated immunosuppression within the tumor microenvironment.
Code name:NZV 930
NZV-930
NZV930
SRF 373
SRF-373
SRF373
Search NCI's Drug Dictionary